CORDIS
EU research results

CORDIS

English EN
PET Imaging in Drug Design and Development

PET Imaging in Drug Design and Development

Objective

The drug development strategy currently pursued by the pharmaceutical industry worldwide is inefficient and unsustainable for the health care system. To keep the latter affordable, drug development should become more efficient and drug treatment should become more “personalized” and “rationalized”. Molecular imaging can play a pivotal role in changing the landscape of drug design/development and improving the health care system. Positron Emission Tomography (PET) imaging, in particular, is the technology that has the potential to lead this fundamental innovation by providing at a much earlier stage reliable answers to key questions emerging during the care cycle: what and where is the disease? Is the disease accurately targeted by the therapy? Is the treatment effective? By answering the questions above, PET imaging has the capacity to render much more effectively the transition from pre-clinical to clinical phase, and to strongly facilitate the development of better drugs at an earlier stage and in a much more sustainable manner. The main obstacle to this change of paradigm in drug design and development is the lack of suitably trained translational scientists directly involved in PET imaging and imaging scientists with high-profile training in chemistry and PET-radiochemistry, which is particularly dramatic in Europe. This consortium is ideally suited to fill this gap, by providing top-quality training to the next generation of translational PET imaging scientists who will play a key role in shaping the future of drug design and development. The PET3D ETN will focus on 15 cutting-edge research projects in the 3 main therapeutic areas (oncology, cardiovascular, central nervous system) that will be conducted by 15 ESRs at 8 European beneficiary Institutions, 6 academic (all having a PET center on site) and 2 non-academic (one with a PET center on site and one big pharmaceutical company) representing the drug design and development terminus of the project.

Coordinator

LOUGHBOROUGH UNIVERSITY

Address

Ashby Road
Le11 3tu Loughborough

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 165 187,34

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

STICHTING VU

Netherlands

VRIJE UNIVERSITEIT BRUSSEL

Belgium

EU Contribution

€ 501 120

UNIVERSITETET I BERGEN

Norway

EU Contribution

€ 572 550,48

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE

Spain

EU Contribution

€ 495 745,92

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Germany

EU Contribution

€ 498 432,96

IMANOVA LIMITED

United Kingdom

EU Contribution

€ 273 287,88

ASTRAZENECA AB

Sweden

EU Contribution

€ 263 659,32

STICHTING VUMC

Netherlands

EU Contribution

€ 510 748,56

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

United Kingdom

EU Contribution

€ 620 515,32

Project information

Grant agreement ID: 675417

Status

Ongoing project

  • Start date

    1 June 2016

  • End date

    31 May 2020

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 912 634,77

  • EU contribution

    € 3 901 247,78

Coordinated by:

LOUGHBOROUGH UNIVERSITY

United Kingdom